Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Novo Nordisk A/S | INDUSTRY |
| TrygFonden, Denmark | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The goal of this parallel-group, two-arm, assessor-blinded, randomised clinical trial is to investigate the effects of reducing physical activity on food intake and satiety in physically active and healthy males, 40-55 years of age.
The main questions it aims to answer are:
Participants will be randomised (1:1) to two weeks of either no intervention (control group) or inactivity. Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day.
Researchers will compare the inactivity group to the control group to see if physical inactivity impairs appetite regulation.
To contextualize the changes in ad libitum food intake driven by two weeks of physical inactivity, a sub-study will assess the effect of GLP-1 infusion on ad libitum food intake compared with a saline control in 20 participants included based on same eligibility criteria as in the main study. The estimated GLP-1 induced change in ad libitum food intake will be descriptively compared to the estimated GLP-1 + inactivity induced change in ad libitum food intake (main-study) to provide context for any attenuation in appetite suppression observed in the main-study. Outcomes related to subjective appetite measures (hunger, satiety, and food preference) will also be assessed in this way.
The primary hypothesis is that GLP-1 infusion will suppress appetite and reduce ad libitum food intake compared with saline control. The secondary hypothesis is that GLP-1 infusion will diminish subjective feelings of hunger and increase satiety.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Inactivity | Experimental | Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day. |
|
| Control | No Intervention | Participants will be instructed to maintain habitual physical activity and dietary habits. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Inactivity | Behavioral | Inactivity will be implemented as cessation of active commuting and all other structured exercise. Furthermore, steps will be reduced to a maximum of 1500 steps/day. |
| Measure | Description | Time Frame |
|---|---|---|
| The change in food intake at an ad libitum meal during GLP-1 infusion | Food intake will be evaluated as ingested food in grams | From baseline (week 0) to follow-up (week 2). |
| Measure | Description | Time Frame |
|---|---|---|
| The change in preference for unhealthy food ( combined score for high fat food, savory food, and sweet food). | Evaluated by visual food stimuli combined with eye tracking | From baseline (week 0) to follow-up (week 2) |
| The change in subjective experience of severity and type of food cravings |
| Measure | Description | Time Frame |
|---|---|---|
| Change in secretion of gut hormones (GLP-1, GIP, PYY, ghrelin, CCK) | From baseline (week 0) to follow-up (week 2) | |
| Change in gastric emptying rate | Measured by surrogate marker paracetamol | From baseline (week 0) to follow-up (week 2) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Inge Holm | Contact | +45 35 45 76 41 | inge.holm@regionh.dk | |
| Bente K Pedersen, Dr Med | Contact | +45 35 45 76 41 | Bente.Klarlund.Pedersen@regionh.dk |
| Name | Affiliation | Role |
|---|---|---|
| Grit Elster Legård, MD, PhD | Centre for Physical Activity Research, Rigshospitalet | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Copenhagen University Hospital | Recruiting | Copenhagen | Denmark |
If the data can be fully anonymized the data can be shared
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluated by the Control of Eating Questionnaire. |
| From baseline (week 0) to follow-up (week 2) |
| The change in subjective feeling of satiety | Evaluated by a visual analogue scale | From baseline (week 0) to follow-up (week 2) |
| The change in subjective felling of hunger | Evaluated by a visual analogue scale | From baseline (week 0) to follow-up (week 2) |
| The change in satiety composite appetite score | Calculated from visual analog scales | From baseline (week 0) to follow-up (week 2) |
| Sub study | Comparison between Ad libitum meal +/- GLP-1 infusion on primary and secondary outcomes of the primary study. | Sub study |
| Change in body composition (body weight, body mass index, lean mass, fat mass) | Based on DXA scans | From baseline (week 0) to follow-up (week 2) |
| Change in physical fitness (maximal aerobic capacity, one repetition max) | From baseline (week 0) to follow-up (week 2) |
| Change in plasma glucose during ad libitum meal | AUC (mol/hour) | From baseline (week 0) to follow-up (week 2) |
| Change in plasma insulin during ad libitum meal | AUC (mol/h) | From baseline (week 0) to follow-up (week 2) |
| Change in plasma c-peptide during ad libitum meal | AUC (mol/hour) | From baseline (week 0) to follow-up (week 2) |
| Change in glucagon supression during ad libitum meal | The % glucagon supression at time 0-30min, 0-60min and 0-120min | From baseline (week 0) to follow-up (week 2) |
| Change in plasma insulin/glucagon ratio during ad libitum meal | Insulin/glucagon at time=30, 60 and 120 | From baseline (week 0) to follow-up (week 2) |
| Change in plasma glucose during mixed meal tolerance test | AUC (mol/hour) | From baseline (week 0) to follow-up (week 2) |
| Change in plasma insulin during mixed meal tolerance test | AUC (mol/hour) | From baseline (week 0) to follow-up (week 2) |
| Change in insulin/c-peptide ratio during mixed meal tolerance test | Insulin/glucagon at time 30min, 60min, 120min and 180 | From baseline (week 0) to follow-up (week 2) |
| Change in plasma c-peptide during mixed meal tolerance test | AUC (mol/hour) | From baseline (week 0) to follow-up (week 2) |
| Change in glucagon supression during mixed meal tolerance test | The % glucagon supression at time 0-30min, 0-60min, 0-120min and 0-180 | From baseline (week 0) to follow-up (week 2) |
| Change in plasma insulin/glucagon ratio during mixed meal tolerance test | Insulin/glucagon at time 30min, 60min, 120min and 180 | From baseline (week 0) to follow-up (week 2) |
| Change in plasma concentration of cytokines (IL-1Ra, IL-6, IL-10, CRP, TNF-α, GDF-15) | From baseline (week 0) to follow-up (week 2) |
| Change in plasma concentration of adipokines (leptin and adiponectin) | From baseline (week 0) to follow-up (week 2) |
| Change in glycaemic variability | CV% derived from free-living continuous glucose monitoring | From baseline (week 0) to follow-up (week 2) |
| Change in glycaemic variability | SD derived from free-living continuous glucose monitoring | From baseline (week 0) to follow-up (week 2) |
| Change in glycaemic variability | Mean glucose derived from free-living continuous glucose monitoring | From baseline (week 0) to follow-up (week 2) |
| Change in glycaemic variability | Time in range derived from free-living continuous glucose monitoring | From baseline (week 0) to follow-up (week 2) |
| Change in physical and mental well-being | Based on scores from WHO5, HAM-DS-S, and GAD-10 questionnaires | From baseline (week 0) to follow-up (week 2) |
| Change in physical and mental well-being | Based on scores from WHO5 questionnaires | From baseline (week 0) to follow-up (week 2) |
| Change in symptoms of depression | Based on scores from HAM-D6-S questionnaires | From baseline (week 0) to follow-up (week 2) |
| Change in symptoms of anxiety | Based on scores from GAD-10 questionnaires | From baseline (week 0) to follow-up (week 2) |
| Change in sleep Quality | Based on scores from Pittsburgh Sleep Quality Index | From baseline (week 0) to follow-up (week 2) |
| Change in plasma peptides | Evaluated by peptidomics | From baseline (week 0) to follow-up (week 2) |
| Change in plasma metabolites | Evaluated by metabolomics | From baseline (week 0) to follow-up (week 2) |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |